Syros Pharmaceuticals (LTS:0LC7) EPS (Basic): $-3.07 (TTM As of Sep. 2024)


LTS:0LC7 Syros Pharmaceuticals Inc LTS:0LC7
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals EPS (Basic)?

Syros Pharmaceuticals LTS:0LC7 12 EPS (Basic) is $-3.07 as of Sep. 2024. GuruFocus rates LTS:0LC7 with a GF Score™ of 12/100.

Syros Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.16. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.07.

Syros Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.16. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.07.

Syros Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2024 was $-0.68. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -3.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Syros Pharmaceuticals  (LTS:0LC7) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Syros Pharmaceuticals EPS (Basic) Related Terms

Syros Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals EPS (Basic) Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.80 -18.20 -13.84 -7.49 -5.81

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.43 -2.22 -0.10 -0.59 -0.16
LTS:0LC7
12GF Score
Syros Pharmaceuticals Inc LTS:0LC7
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Syros Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-164.574-0)/28.326
=-5.81

Syros Pharmaceuticals's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.396-0)/39.336
=-0.16

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-3.07 mean?
Syros Pharmaceuticals (LTS:0LC7) has a EPS (Basic) of $-3.07 as of Sep. 2024. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Syros Pharmaceuticals and its competitors.
Is Syros Pharmaceuticals' EPS (Basic) too high?
Syros Pharmaceuticals' current EPS (Basic) is $-3.07. Overall, Syros Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Syros Pharmaceuticals' EPS (Basic) compare to AFMDQ and BTAX?
Syros Pharmaceuticals' EPS (Basic) of $-3.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Syros Pharmaceuticals and its competitors. Syros Pharmaceuticals's current EPS (Basic) is $-3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syros Pharmaceuticals stock overvalued right now?
Syros Pharmaceuticals (LTS:0LC7) has a current EPS (Basic) of $-3.07. The current EPS (Basic) is $-3.07. Syros Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Syros Pharmaceuticals (LTS:0LC7), the current EPS (Basic) is $-3.07 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for LTS:0LC7

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price